arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Kymera Therapeutics, Inc.

KYMR

$107.49 ▲ +1.07 (+1.01%) at close

8 Visible periods

28 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Neutral

auto_awesome

Analytical Summary

Kymera Therapeutics, Inc. shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $9.1B

Dividend Yield —

Revenue Growth -16.7% ↗

Op. Margin None

ROIC -22.1% ↗

FCF / Share $-2.77 →

Trailing P/E —

Price / Book 5.5x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

8-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$39.21M

↓ -16.7% —

Net Income Profit after all expenses

$-311.35M

↓ -39.1% —

Operating Margin Operating profit as % of sales

-210.6%

↑ +38.8% —

FCF / Share Free cash flow per share

$-2.77

— -0.4% —

Health Breakdown

Returns ↑

Financial Health ↓

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Revenue Growth YoY (%)	-16.7% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-309%)	-40.1% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-601%)	67.8% Excellent ↓ Excellent Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+748%)	-35.7% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-546%)	114.0% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+1325%)	1060.0% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+13150%)	—	—
EPS Growth YoY (%)	-23.8% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-18.3% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	12.2% Fair Fair Year-over-year change in earnings per share Optimal: > 10%	-37.3% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—
Net Income Growth YoY (%)	-39.1% Weak ↓ Weak Declining Year-over-year change in net income	-52.3% Weak ↑ Weak Improving Year-over-year change in net income	5.1% Fair ↑ Fair Improving Year-over-year change in net income	-54.5% Weak ↑ Weak Improving Year-over-year change in net income	-119.8% Weak Weak Year-over-year change in net income	-10.5% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	-0.4% Weak ↑ Weak Improving Year-over-year change in free cash flow	-17.4% Weak ↓ Weak Declining Year-over-year change in free cash flow	18.6% Good Good Year-over-year change in free cash flow	-6.3% Weak Weak Year-over-year change in free cash flow	—	—	—	—
Revenue CAGR 3Y (%)	-5.7% Weak ↓ Weak Declining Compound annual revenue growth over 3 years	-13.5% Weak ↓ Weak Declining Compound annual revenue growth over 3 years	32.2% Excellent Excellent Compound annual revenue growth over 3 years	151.8% Excellent Excellent Compound annual revenue growth over 3 years	—	—	—	—
Revenue CAGR 5Y (%)	2.9% Caution Caution Compound annual revenue growth over 5 years	74.2% Excellent Excellent Compound annual revenue growth over 5 years	—	—	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Operating Margin (%) (%)	—	—	-210.6% Weak → Weak Stable Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1504%)	-344.4% Weak ↓ Weak Declining Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2396%)	-138.0% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1020%)	-136.1% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1007%)	—	—
Effective Tax Rate (%) (%)	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—	—	—	—	—
Profit Margin (%) (%)	—	-475.6% Weak ↓ Weak Declining Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-4063%)	-187.0% Weak ↑ Weak Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1658%)	-330.6% Weak ↓ Weak Declining Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2855%)	-137.6% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1247%)	-134.0% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1216%)	—	—
FCF Margin (%) (%)	—	-440.5% Weak ↓ Weak Declining Free cash flow as a percentage of revenue Optimal: > 10%	-174.7% Weak ↓ Weak Declining Free cash flow as a percentage of revenue Optimal: > 10%	-333.0% Weak ↓ Weak Declining Free cash flow as a percentage of revenue Optimal: > 10%	-179.2% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	232.2% Excellent Excellent Free cash flow as a percentage of revenue Optimal: > 10%	—	—
FCF / Net Income (x)	0.75x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.93x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.93x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	1.01x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	1.30x Good ↑ Good Improving Free cash flow relative to reported net income Optimal: > 1x	-1.73x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	-0.42x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Return on Invested Capital (%)	-22.1% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-24.7% Weak → Weak Stable Return earned on debt + equity capital invested Optimal: > 10%	-33.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-26.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-17.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-12.9% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	44.8% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-20.0% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-26.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-28.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-26.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-16.6% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-9.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	-36.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-19.7% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-231%)	-26.8% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-279%)	-37.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-348%)	-31.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-311%)	-21.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-245%)	-16.1% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-207%)	55.4% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+270%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Interest Coverage (x)	-1119.87x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-1270.07x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-1021.79x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-900.87x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-636.27x Weak → Weak Stable Operating income divided by interest expense Optimal: > 5x	-402.64x Weak Weak Operating income divided by interest expense Optimal: > 5x	-917.50x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-357.01M	$-120.26M	$-109.97M	$-68.39M	$-47.98M	$-31.00M	$-76.02M	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Revenue per Share (USD)	$0.46	$0.63	$1.35	$0.87	$1.52	—	—	—
Basic EPS, GAAP (USD)	$-3.69	$-2.98	$-2.52	$-2.87	$-2.09	—	—	—
Free Cash Flow per Share (USD)	$-2.77	$-2.76	$-2.35	$-2.89	$-2.72	—	—	—
Book Value per Share (USD)	$19.42	$12.88	$7.11	$8.91	$8.92	$6.38	$-38.56	—
Tangible Book Value per Share (USD)	$19.42	$12.88	$7.11	$8.91	$8.92	$6.38	$-38.56	—
Basic Weighted Avg Shares (shares)	84.49M	75.04M	58.37M	53.93M	47.99M	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Working Capital (USD)	$788.00M	$442.50M	$319.63M	$348.07M	$358.73M	$191.72M	$58.27M	—
Total Equity (USD)	$1.58B	$835.62M	$394.97M	$490.15M	$459.64M	$283.89M	$-74.41M	$-34.44M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Sales/Revenue/Turnover (USD)	$39.21M	$47.07M	$78.59M	$46.83M	$72.83M	$34.03M	$2.93M	—
Depreciation Expense (USD)	$8.31M	$7.37M	$3.56M	$2.98M	$2.40M	$1.76M	$825.00K	—
Net Income, GAAP (USD)	$-311.35M	$-223.86M	$-146.96M	$-154.81M	$-100.22M	$-45.59M	$-41.25M	—
Operating Cash Flow (USD)	$-232.89M	$-194.50M	$-102.83M	$-153.09M	$-128.95M	$88.13M	$17.91M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 8 years · 29 quarters

Kymera Therapeutics, Inc.

Analytical Summary

8-Year Financial Trajectory

Health Breakdown

Statement lens

Benchmark Lens

Percentile Rankings

Peer Comparison

Compare KYMR with peers